Evidence map›Paper›PMID 34866524›Full record

ArticleBioengineered2021

LncRNA DDX11 antisense RNA 1 promotes EMT process of esophageal squamous cell carcinoma by sponging miR-30d-5p to regulate SNAI1/ZEB2 expression and Wnt/β-catenin pathway.

Yanli Guo, Pingping Sun, Wei Guo, Qing Yin, Junshu Han, Supeng Sheng, Jia Liang, Zhiming Dong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Roles of long non-coding RNAs in oesophageal cancer pathogenesis.International journal of experimental pathology · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yanli GuoHebei Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Pingping SunBeijing Shijitan Hospital, Capital Medical University, Beijing, China.
Wei GuoHebei Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Qing YinHebei Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Junshu HanHebei Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Supeng ShengHebei Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Jia LiangHebei Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Zhiming DongHebei Cancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Fourth Hospital of Hebei Medical University · CNHebei Medical University · CNBeijing Shijitan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

LncRNA DDX11 antisense RNA 1 (DDX11-AS1) is recognized as having an imperative oncogenic role in different types of human cancer. Nevertheless, the functions, as well as the basic mechanisms of DDX11-AS1 in the EMT process of esophageal squamous cell carcinoma (ESCC), are yet to be clarified. In this research, high DDX11-AS1 expression was detected in ESCC cells as well as tissues and was linked to the poor prognosis of patients with ESCC. DDX11-AS1 promoted cell proliferation, migration, invasion ability and epithelial mesenchymal transition (EMT) process in vitro. Mechanistic analysis depicted that DDX11-AS1 may function as a ceRNA through sponging miR-30d-5p to upregulate the expression of SNAI1 and ZEB2. Meanwhile, overexpression of DDX11-AS1 might cause the activation of the Wnt/β-catenin signaling pathway via targeting miR-30d-5p. On the whole, the findings of this research illustrate that DDX11-AS1 may act as an EMT-related lncRNA to advance ESCC progression through sponging miR-30d-5p to regulate SNAI1/ZEB2 expression and activate the Wnt/β-catenin pathway, which indicates that it might serve as a probable therapeutic target for ESCC.

Indexed as

Base SequenceBinding, CompetitiveCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaGene Expression Regulation, NeoplasticHumansMicroRNAsMultivariate AnalysisNeoplasm InvasivenessPrognosisRNA, Long NoncodingSnail Family Transcription FactorsMicroRNAsMIRN30a microRNA, humanRNA, Long NoncodingSNAI1 protein, humanSnail Family Transcription FactorsTransforming Growth Factor betaZEB2 protein, humanZinc Finger E-box Binding Homeobox 2DDX11-AS1epithelial mesenchymal transitionEsophageal squamous cell carcinomamiR-30d-5pSNAI1Wnt signaling pathwayZEB2

Identifiers

PMID34866524
PMCPMC8810181
OpenAlexW4200004953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.